Contact

Mansour M. Zadeh, PhD

Distinguished Professor

Personal Statement:

Dr. Mansour M. Zadeh is a cellular and molecular immunologist. Dr. Zadeh is a Distinguished Professor in Medicine and the Director of The Center for Mucosal & Microbiome Biology at the UT Health San Antonio – Joe R. & Teresa Lozano Long School of Medicine. His laboratory’s work is tightly focused on the interaction of gut microbiome and the associated metabolites (e.g., vitamin B12) with the hosts during steady states and proinflmammatory diseases such as inflammatory bowel disease (IBD). Dr. Zadeh’s goal is to robustly establish an advanced scientific platform in cellular and molecular mucosal immunology and microbiome research by supporting the education of both basic and clinical scientists. Dr. Zadeh’s research and educational endeavors are geared toward creating an environment that facilitates a commitment to innovative research excellence and patient care.


Education

Doctor of Philosophy in Cellular & Molecular Immunology
1991 · Johannes Gutenberg University

Master of Science in Cellular & Molecular Immunology
1989 · Johannes Gutenberg University

Bachelor of Science in Cellular & Molecular Biology
1986 · Johannes Gutenberg University/Germany

Research

Dr. Mansour Zadeh is an immunologist with over 25 years of expertise in the fields of inflammation, systemic/mucosal immunology, infection, and vaccine delivery. He is also experienced in working with various therapeutic approaches that focus on the role of innate immune cells–particularly dendritic cells, and how these cells determine the activation and differentiation of T lymphocytes, including T cells, such as TH17 or extrathymic regulatory T cells (Tregs) in steady state, during infection, and throughout autoinflammatory intestinal disorders such as inflammatory bowel disease (IBD) and necrotizing enterocolitis (NEC). In his opinion, understanding the molecular mechanisms underlying intestinal immune regulation is most effective when host interactions with intestinal bacterial species and their bacterial products are fully understood, and when the critical molecules that culminate in inflammation or anti-inflammatory responses are identified. Thus, his research is firmly centered on the specifics of beneficial gut microbes, their unique properties, and their role in the induction of stimulatory or regulatory signals in innate cells and T lymphocytes, contributing directly to further proinflammation or regulation of inflammatory diseases (IBD, NEC). Pragmatically, his research is tightly entwined with generating novel therapies for intestinal disorders (e.g. NEC) using beneficial bacteria such as P. UF1 to significantly regulate induced pathogenic inflammation in sufferers who urgently need it. Furthermore, his team also established a novel targeted vaccine platform, dual route vaccine, to mobilize protective humoral immunity against infectious agents, including botulinum neurotoxin A complex (BoNT/A), in animals and man. The same dual route vaccine platform is currently optimized to elucidate the efficacy of probiotic bacterium, P. UF1, expressing PD-1 molecule to generate neutralizing antibody against PD-1 to inhibit T cell exhaustion and to protect against melanoma cancer. This elegant and less costly approach will be further developed and tested in higher animals, including dogs affected by melanoma and hopefully in phase 1 clinical trial in man in the near future.